There are several unforeseen challenges in the current clinical trials for the treatment of DMD, including immune responses to the generated mini-dystrophin in the ongoing gene therapies and inconsistent evidence of dystrophin production in muscle tissues. This evidence concerns the gene DMD and Duchenne muscular dystrophy.